2026 ICD-10-CM Diagnosis Code Q85.00Neurofibromatosis, unspecified

ICD-10-CM Codes›Q00-Q99›Q80-Q89›Q85

ICD-10-CM Q85.00
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

Q85.00 is a billable ICD-10-CM diagnosis code for neurofibromatosis, unspecified. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The code is exempt from POA reporting. Coders also document this condition as diffuse neurofibroma. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Nervous system congenital anomalies.

Code Identity

ICD-10-CM Code
Q85.00
Billable Status
Yes — Valid for Submission
Code Describes
Neurofibromatosis, unspecified
Short Description
Neurofibromatosis, unspecified
Same as the full description in the CMS dataset.
Parent Code
Q85.0
Neurofibromatosis (nonmalignant)

Code Classification

ChapterQ00-Q99Congenital malformations, deformations and chromosomal abnormalities
SectionQ80-Q89Other congenital malformations
CategoryQ85Phakomatoses, not elsewhere classified
This CodeQ85.00Neurofibromatosis, unspecified

Present on Admission (POA)Billing

Q85.00 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Diffuse neurofibroma
  • Neurofibromatosis syndrome
  • Pulmonary hypertension in neurofibromatosis
  • Pulmonary hypertension in systemic disorder
  • Scoliosis in neurofibromatosis

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Neurofibromatosis(multiple) (nonmalignant)

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR MAL004
Nervous system congenital anomalies
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Diffuse Neurofibroma

    a rare neurofibroma with an infiltrative growth pattern. it involves the skin and subcutaneous tissue and grows in a plaque-like fashion. malignant transformation is rare.

Patient EducationClinical

Neurofibromatosis

Neurofibromatosis is a genetic disorder of the nervous system. It mainly affects how nerve cells form and grow. It causes tumors to grow on nerves. You can get neurofibromatosis from your parents, or it can happen because of a mutation (change) in your genes. Once you have it, you can pass it along to your children.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert Q85.00 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
237.70 Neurofibromatosis NOS
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About Q85.00Overview

Is Q85.00 (Neurofibromatosis (nonmalignant)) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report neurofibromatosis, unspecified on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Is Q85.00 exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for neurofibromatosis, unspecified on inpatient claims.

What is the ICD-9 equivalent of Q85.00?

Under the General Equivalence Mappings, neurofibromatosis, unspecified converts to ICD-9-CM 237.70 (neurofibromatosis NOS). The mapping is a direct match.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.